why choose us

First received: April 27, 2023

Clinical Trial: Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Oligometastatic Disease

Study Type: INTERVENTIONAL


Official Title: Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered With or Without STING-Agonist IMSA101 in Patients With O

Brief Summary: Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with NSCLC or RCC

Read more